The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Lupus Treatment Advances Lag Behind Other Rheumatic Diseases

Lupus Treatment Advances Lag Behind Other Rheumatic Diseases

August 11, 2016 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Other strategies for B cell interventions target B cell surface receptors, soluble modulators that lead to B cell proliferation and differentiation, and B cell signaling mechanisms downstream of the B cell receptor, Dr. Dall’Era noted. Drugs recently under investigation for BAFF-blockade include blisibimod, tabalumab and atacicept, which is unique in that it targets both BAFF and APRIL (a proliferation-inducing ligand).

You Might Also Like
  • Dr. Peter Schur Discusses Lupus Treatment, Management Advances in Past 50 Years
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • Lupus Expert Calls for Better Research, Outcomes of Clinical Trials
Explore This Issue
August 2016

Evidence for the role of type 1 inter­ferons in SLE includes the fact that treatment with interferon-alpha leads to a lupus-like disease, risk polymorphisms for lupus are present in interferon-regulated genes, interferon signature is present in peripheral blood mononuclear cells and in tissues from lupus patients, and the level of expression of interferon-inducible genes correlates with disease activity. Drugs that have been studied include rontalizumab and sifalimumab, whose development have been discontinued; and anifrolumab, which is continuing in Phase III trials.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

More than 500 current clinical trials of lupus therapies point toward a bright future, increasing the likelihood of demonstrating efficacy of novel experimental agents. —Dr. Dall’Era

Advances in Treating Lupus Nephritis

A major manifestation of SLE, lupus nephritis, is also being targeted with new treatment strategies, Dr. Dall’Era reported. Conventional induction treatment involves high doses of glucocorticoids, along with such drugs as mycophenolate mofetil or cyclophosphamide. An emerging strategy is multi-target therapy, she said, “already standard of care in the treatment of patients who have undergone organ transplant.” One recent small trial demonstrated the efficacy of the combination of tacrolimus and mycophenolate mofetil when compared with intravenous cyclophosphamide for induction treatment of lupus nephritis. Another trial in progress is studying the combination of voclosporin (a next generation calcineurin inhibitor) in combination with mycophenolate mofetil.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Another active area of research involves novel ways to use rituximab for the treatment of lupus nephritis. The Rituxilup trial, with European and American collaborators, is assessing the use of rituximab instead of, rather than as add-on therapy to, oral steroids. Rituximab is being given in combination with two doses of intravenous steroids and followed by mycophenolate mofetil. In the CALIBRATE trial, patients with lupus nephritis are undergoing an induction regimen of rituximab and two doses of intravenous cyclophosphamide, followed by belimumab maintenance.


Larry Beresford is an Oakland, Calif.-based freelance medical journalist.

References

  1. Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response. Ann Rheum Dis. 2012 Aug;71(8):1343–1349.

Pages: 1 2 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: advances, California Rheumatology Alliance 2016, Lupus, patient care, Research, Rheumatic Disease, SLE, Treatment, updateIssue: August 2016

You Might Also Like:
  • Dr. Peter Schur Discusses Lupus Treatment, Management Advances in Past 50 Years
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • Lupus Expert Calls for Better Research, Outcomes of Clinical Trials
  • The ACR’s Collaborative Initiatives Promote Awareness of Lupus, Rheumatic Diseases

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)